• Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Spain

  • Study on the Safety and Effectiveness of 19CP02 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated Drugs:
    Belgium Finland The Netherlands

  • Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Belgium The Netherlands

  • Study on the Safety and Tolerability of A3907 for Adults with Primary Sclerosing Cholangitis (PSC)

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Poland Spain

  • Study on [68Ga]Ga-PentixaFor for Detecting Multiple Myeloma in Patients Under 66 Eligible for Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on Tecovirimat for Treating Monkeypox in Patients with Confirmed Infection

    Not recruiting

    3 1 1
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Norway +2

  • Study on Long-Term Safety of Gene Therapy for Pyruvate Kinase Deficiency Using Autologous CD34+ Cells in Adults and Children

    Not recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study on Octreotide for Nutritional Recovery After Surgery in Esophageal or Gastric Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Sweden

  • Study on Ganciclovir and Valganciclovir for Preventing Cytomegalovirus in High-Risk Heart Surgery Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study on Colchicine for Reducing Inflammation in Patients with Type 1 Diabetes

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark

powered by